论文部分内容阅读
从分子水平探讨胃癌和直肠癌患者血清PHA识别的糖蛋白糖链结构表达的特异性及其与肿瘤发生,诊断和治疗的关系,建立了一种血清 PHA 识别的糖蛋白糖链 ELISA 检测方法,并对直肠癌,手术治疗前后的胃癌患者,良性消化道疾病患者及正常人血清进行检测,结果表明59例胃癌患者血清 PHA 识别的糖蛋白表达阳性率为71.2％;16例直肠癌患者阳性率为50.0％,而良性疾病患者为15.2％(5/33),正常人仅为 7.7％(2/26)。14例阳性胃癌患者行胃癌根治术后2～3周阳性者仅为2例。初步提示血清PHA识别的糖蛋白的检测对胃癌、直肠癌的诊断具有一定意义。
The specificity of the expression of glycoprotein sugar chains recognized by serum PHA in patients with gastric cancer and rectal cancer was explored at the molecular level and its relationship with tumorigenesis, diagnosis, and treatment. A serum PHA-recognized glycoprotein glycan ELISA detection method was established. The detection of rectal cancer, gastric cancer patients before and after surgery, benign gastrointestinal diseases and normal human serum were performed. The results showed that the positive rate of serum glycoprotein recognition in PHA in 59 cases of gastric cancer was 71.2%; the positive rate of 16 rectal cancer patients It was 50.0%, while patients with benign disease were 15.2% (5/33) and normal individuals were only 7.7% (2/26). Only 2 cases were positive in 2 to 3 weeks after radical gastrectomy in 14 cases of positive gastric cancer. It is suggested that the detection of serum glycoproteins detected by PHA has a certain significance for the diagnosis of gastric cancer and rectal cancer.